Vaxart Appoints W. Mark Watson as Lead Independent Director

Core Viewpoint - Vaxart, Inc. is advancing its oral vaccine platform and has appointed W. Mark Watson as Lead Independent Director to enhance governance and align board interests with stockholders [1][3] Company Developments - Vaxart is in the process of adopting a Director stock ownership policy to ensure alignment of interests between the Board and stockholders [3] - A special meeting of stockholders is scheduled for September 19, 2025, to discuss a reverse stock split proposal, with voting encouraged until September 18, 2025 [4][5] Leadership Background - W. Mark Watson brings over 50 years of experience, including significant roles at Deloitte and various biotech companies, and has been on Vaxart's Board since August 2022 [2] - Watson emphasizes the importance of regaining Nasdaq compliance for the company's long-term success [3] Vaccine Development - Vaxart is developing oral recombinant vaccines that can be stored without refrigeration, targeting diseases such as coronavirus, norovirus, and influenza, as well as a therapeutic vaccine for HPV [6][7]